On Friday, DaVita HealthCare Partners Inc (NYSE:DVA)’s shares inclined 0.90% to $82.19.
DaVita HealthCare Partners Inc (DVA) one of the nation’s largest and most innovative health care communities, is celebrating the anniversary of its teammate-chosen name “DaVita,” which in Italian means “giving life.”
Asking teammates to contribute to culture-shaping decisions has led to DaVita Kidney Care continuously holding a coveted place on The WorldBlu List of Most Democratic Workplaces™. In fact, it is the only Fortune 500™ company to have appeared on the list for the past eight years.
Additionally, the four interior “seasonal gardens” inside the building reflect the seasonal colors, textures, plantings and activities of Colorado. Every floor also features a “Zen room,” where teammates can find a secluded, relaxing place to work, if necessary.
Company leadership assists create an intentional, democracy-driven culture that is distinctive in corporate America and has received recognition from numerous third parties. Aside from WorldBlu, DaVita Kidney Care was recognized recently by The Denver Post as a 2015 Top Workplace for the fourth successive year since the company moved to Denver.
Tangible success of DaVita’s unwavering commitment to patients can be seen in DaVita Kidney Care’s performance in the Five-Star Rating system, recently released by the Centers for Medicare and Medicaid. The company outperformed the industry average by 138 percent.
DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals.
Vimicro International Corporation (ADR) (NASDAQ:VIMC)’s shares gained 0.57% to $12.33.
Vimicro International Corporation (ADR) (VIMC) a leading video surveillance technology and solution provider in China, recently declared that its Board of Directors (the “Board”) has received a non-binding proposal letter, dated June 21, 2015, from Dr. Zhonghan (John) Deng, founder, chairman and chief executive officer of the Company, and Zhaowei (Kevin) Jin, co-chief executive officer and a board member of the Company (the “Buyer Group”) to acquire all of the outstanding ordinary shares of the Company not already owned by the Buyer Group for US$13.50 in cash per American depositary share (“ADS”, each representing four ordinary shares), or about US$3.375 per ordinary share, which represents an about 22.7% premium above the average closing price of the Company’s ADSs over the last 90 trading days (the “Transaction”). A copy of the proposal letter is attached hereto as Exhibit A.
The Board has formed a special committee comprising of independent directors to consider this proposal.
The Board cautions the Company’s shareholders and others considering trading in its securities that the Board just received the non-binding proposal letter from the Buyer Group and no decisions have been made with respect to the Company’s response to the Transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.
Vimicro International Corporation, together with its auxiliaries, designs, develops, and markets semiconductor products with multimedia applications in Mainland China, Hong Kong, and the United States. The company operates through Video surveillance Solutions and Video Processor segments.
At the end of Friday’s trade, Allison Transmission Holdings Inc (NYSE:ALSN)‘s shares dipped -0.26% to $30.34.
Allison Transmission Holdings Inc (ALSN) declared that it has been working with the U.S. Environmental Protection Agency (EPA) and National Highway Traffic Safety Administration (NHTSA) as they consider revisions to the ‘Phase I’ Model Year 2014-2018 rule regarding fuel efficiency and greenhouse gas emission (GHG) standards for medium and heavy-duty vehicles. The revisions would potentially extend the Phase I program into the middle of the next decade.
Allison is the world’s largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles and is a leader in hybrid-propulsion systems for city buses. Celebrating its centennial in 2015, the company continues to focus on fully understanding and addressing the needs of its customers. Accordingly, Allison has embraced the opportunity to collaborate with EPA and NHTSA to align any regulatory effort with the technological and commercial realities of the tractor and vocational vehicle markets.
Allison Transmission Holdings, Inc., together with its auxiliaries, designs, manufactures, and sells commercial and defense fully-automatic transmissions for medium- and heavy-duty commercial vehicles, and medium- and heavy-tactical U.S. defense vehicles. It offers transmissions for various applications, counting distribution, refuse, construction, fire, and emergency on-highway trucks; school, transit, and hybrid-transit buses; motor homes; energy, mining, and construction off-highway vehicles and equipment; and wheeled and tracked defense vehicles.
Perrigo Company plc Ordinary Shares (NYSE:PRGO), ended its Friday’s trading session with -2.07% loss, and closed at $184.38.
Mylan N.V. issued the following statement regarding Abbott Laboratories’ declared intention to support Mylan’s offer to acquire Perrigo Company plc (PRGO) and vote in favor of this acquisition at Mylan’s forthcoming shareholder meeting. Abbott is presently Mylan’s largest shareholder, owning 14.5% of Mylan’s outstanding shares, and is an important long-term stakeholder of Mylan through various manufacturing partnerships.
Mylan Executive Chairman Robert J. Coury stated: “We are very happy that, while Abbott is under no obligation to do so, Abbott has voluntarily chosen to express its support of Mylan, our planned growth plan and stand-alone strategy, and our projected combination with Perrigo. When we attained Abbott’s non-U.S. developed markets specialty and branded generics business earlier this year, we gained an important stakeholder in Abbott, which understands the powerful potential of our platform, and the critical importance of our scale and breadth across our distribution channels. We are grateful for Abbott’s support of our long-term vision, which we firmly believe will continue to deliver strong near-term and long-term returns in this rapidly evolving industry and will promote the sustainable success of Mylan’s business.”
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, in addition to in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
